Parth R. Majmudar
YOU?
Author Swipe
View article: S8 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S8 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 8
View article: S1 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S1 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 1
View article: S8 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S8 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 8 Legend
View article: S3 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S3 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 3 Legend
View article: S5 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S5 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 5 Legend
View article: S6 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S6 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 6
View article: S7 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S7 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 7
View article: S3 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S3 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 3
View article: Table S1 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
Table S1 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Table S1
View article: S6 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S6 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 6 Legend
View article: S2 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S2 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 2 Legend
View article: S5 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S5 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 5
View article: The neural stem cell gene PAFAH1B1 controls cell cycle progression, DNA integrity, and paclitaxel sensitivity of triple-negative breast cancer cells
The neural stem cell gene PAFAH1B1 controls cell cycle progression, DNA integrity, and paclitaxel sensitivity of triple-negative breast cancer cells Open
Triple-negative breast cancer (TNBC) is a highly aggressive disease with limited approved therapeutic options. The rapid growth and genomic instability of TNBC cells make mitosis a compelling target, and a current mainstay of treatment is …
View article: Targeting the mitotic kinase NEK2 enhances CDK4/6 inhibitor efficacy by potentiating genome instability
Targeting the mitotic kinase NEK2 enhances CDK4/6 inhibitor efficacy by potentiating genome instability Open
View article: Supplemental Figure 2 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer
Supplemental Figure 2 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer Open
Loss of YES1 causes chromosomal instability dsDNA breaks, and decreased growth in TNBC cells.
View article: Supplemental Table 2 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer
Supplemental Table 2 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer Open
Significant GOs for Dot Plots
View article: Supplemental Figure 3 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer
Supplemental Figure 3 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer Open
YES1 silencing alters mitotic gene expression and cell cycle progression in SUM159 cells.
View article: Supplemental Table 4 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer
Supplemental Table 4 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer Open
Overlapping DEGs in YES1i
View article: Supplemental Table 1 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer
Supplemental Table 1 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer Open
Methods RR_IDs
View article: Supplemental Figure 4 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer
Supplemental Figure 4 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer Open
YES1 is essential for microtubule function and centrosome homeostasis in SUM159 cells.
View article: Data from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer
Data from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer Open
Clinical trials examining broad-spectrum Src family kinase (SFK) inhibitors revealed significant dose-limiting toxicities, preventing advancement for solid tumors. SFKs are functionally heterogeneous, thus targeting individual members is a…
View article: Supplemental Table 3 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer
Supplemental Table 3 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer Open
Overlapping DEGs sgYES1
View article: Supplemental Figure 5 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer
Supplemental Figure 5 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer Open
Pharmacologically targeting YES1 induces chromosomal instability, centrosome dysfunction, and multipolar spindle formation.
View article: Supplemental Figure 1 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer
Supplemental Figure 1 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer Open
Expression of SFK family members other than YES1 is not predictive of outcomes in patients with basal breast cancer.
View article: Supplemental Figure 6 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer
Supplemental Figure 6 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer Open
YES1 inhibition improves taxane efficacy in resistant TNBC in vitro.
View article: Supplemental Figure 7 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer
Supplemental Figure 7 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer Open
YES1 inhibition re-sensitizes paclitaxel-resistant SUM159 cells, in vitro.
View article: Supplemental Figure 8 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer
Supplemental Figure 8 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer Open
Treatment with YES1i, paclitaxel, or the combination is non-toxic, in vivo.
View article: Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer
Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer Open
Clinical trials examining broad-spectrum Src family kinase (SFK) inhibitors revealed significant dose-limiting toxicities, preventing advancement for solid tumors. SFKs are functionally heterogeneous, thus targeting individual members is a…
View article: Disruption of CDK7 signaling leads to catastrophic chromosomal instability coupled with a loss of condensin-mediated chromatin compaction
Disruption of CDK7 signaling leads to catastrophic chromosomal instability coupled with a loss of condensin-mediated chromatin compaction Open
View article: Table S1 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
Table S1 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Table S1